Author/Authors :
Hatami, Behzad Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences,Tehran, Iran , Rabbani, Amirhassan Taleghani Hospital - Department of Transplant & Hepatobiliary Surgery - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ketabi Moghadam, Pardis Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences,Tehran, Iran , Rajabnia, Mohsen Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences,Tehran, Iran , Borhany, Hamed Taleghani Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) that is known as CO-
VID-19 is a new emerging respiratory infection attributed to novel coronavirus, firstly intro-
duced in Wuhan, China, at the end of 2019. This infection is still of great concern because of
various presentations of the disease, which are not fully understood. The manifestations of this
virus among liver transplanted patients would be more challenging in the setting of immuno-
suppression. The focus of this study is to introduce different presentations of this virus in five
liver transplant recipients referred to the gastroenterology ward of Taleghani Hospital, a teach-
ing referral hospital in Tehran, Iran. These patients were started on different types of therapies
for coronavirus infection, from only supportive care up to remdisivir infusion and hemoperfu-
sion based on the severity of the disease. Additionally, they were advised to continue all their
immunosuppressant agents with adjustment except for CellCept that was withheld.
Keywords :
COVID-19 , Liver Transplant , Recipients , Iran
